logo
  

Carrick Collaborates With Roche To Evaluate Samuraciclib Combination To Treat HR+ Breast Cancer

Carrick Therapeutics said that it has collaborated with Roche to evaluate a novel combination of Carrick's samuraciclib and Roche's giredestrant in CDK4/6i resistant HR+, HER2- metastatic breast cancer.

The collaboration will utilize Roche's MORPHEUS Phase 1b/2 platform for rapid and efficient combination development, with upfront randomization versus a control group.

The new study expands Carrick's portfolio of clinical trials with samuraciclib, which is also being evaluated in a Phase 2a study in combination with fulvestrant for CDK4/6i resistant HR+, HER2- metastatic breast cancer.

Other ongoing studies include samuraciclib for the treatment of triple negative breast cancer (TNBC) and prostate cancer - all settings in which CDK7 has been shown to act as a regulator of transcription, the cell cycle and endocrine receptor signalling.

As per the agreement, each company is supplying its respective anti-cancer agent to support the trial.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Salt Lake City, Utah-based Huish Outdoors is recalling Oceanic Adult Dry Top Snorkels sold exclusively at Costco citing risk for drowning, U.S. Consumer Product Safety Commission said. The recall involves about 76,000 units of Oceanic Adult Dry Top Snorkels. The recall was initiated after Oceanic received 13 reports of the snorkels leaking. Boeing expects Europe's commercial aviation fleet to need 8,705 new airplanes through 2040 to cater to the growing leisure travel market in the region and fleet replacements with more fuel-efficient models, according to the Boeing's 2021 Commercial Market Outlook (CMO), an annual forecast of long-term demand for commercial airplanes and services. The U.S. Food and Drug Administration authorized marketing of a software developed by Paige.AI, a provider of AI-based digital diagnostics, which could help pathologists to identify prostate cancer. The software, called Paige Prostate, is the first and only artificial intelligence or AI-based pathology product to receive FDA approval for in vitro diagnostic or IVD use in detecting cancer...
Follow RTT